Inventor · disambiguated record
John Dipersio
Also filed as: DIPERSIO JOHN · DIPERSIO JOHN F
5 granted patents·16 pending applications·4 citations·filing 2017–2025
68Inventor score
Files withWASHINGTON UNIVERSITY ST LOUIS9UNIV WASHINGTON5MEDICAL COLLEGE WISCONSIN INC3CHRISTOPHER MATTHEW1DIPERSIO JOHN F1
Top patents by PatentIndex Score
21 records- 0181US11696926B2Methods and compositions for treatment of cancerCHRISTOPHER MATTHEW·Filed 2020·Granted Jul 11, 2023·2 cites·9 claims
- 0280US11597917B2In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2018·Granted Mar 7, 2023·2 cites·26 claims
- 0377US2025082785A1Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptorsWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 0473US2025101099A1Chimeric antigen receptor t cells (car-t) for the treatment of cancerWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 0572US2023332112A1Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of DisordersMEDICAL COLLEGE WISCONSIN INC·Filed 2023·Application pending·0 cites
- 0672US2025043243A1Methods for genome-editing and activation of cellsWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 0771US12304941B2Suppression of cytokine release syndrome in chimeric antigen receptor cell therapyWASHINGTON UNIVERSITY ST LOUIS·Filed 2022·Granted May 20, 2025·0 cites·15 claims
- 0870US2024150428A1Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignanciesWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 0965US2025188428A1Novel in vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced hscs for therapy of disordersMEDICAL COLLEGE WISCONSIN INC·Filed 2025·Application pending·0 cites
- 1058US2025381168A1Vla4 inhibitors and uses thereofWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 1158US2020054675A1Suppression of cytokine release syndrome in chimeric antigen receptor cell therapyUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 1256US12350349B2Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptorsDIPERSIO JOHN F·Filed 2017·Granted Jul 8, 2025·0 cites·31 claims
- 1356US2025064894A1Methods and compositions for enhancement of tumor immunogenicity and stimulating anti-tumor immune responses in an animalWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 1456US2020040056A1Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignanciesUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 1556US2020109364A1Methods for genome-editing and activation of cellsUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 1654US2020071397A1Chimeric antigen receptor t cells (car-t) for the treatment of cancerUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 1751US2023366893A1Methods to determine risk of neurotoxicityWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Application pending·0 cites
- 1849US2023210952A1Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cellsWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Application pending·0 cites
- 1948US2021299223A1Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumorUNIV WASHINGTON·Filed 2019·Application pending·0 cites
- 2042US2019328706A1Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereofUNIV SAINT LOUIS·Filed 2019·Application pending·0 cites
- 2140US12496303B2Conditioning agents for use in allogeneic hematopoietic stem cell transplantationPERSAUD STEPHEN·Filed 2021·Granted Dec 16, 2025·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when John Dipersio files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →